NCT03093831 2023-10-11Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaNational Cancer Centre, SingaporePhase 2 Terminated5 enrolled
NCT02109224 2015-08-20Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNational Cancer Institute (NCI)Phase 1 Terminated72 enrolled